{
  "$schema": "folio-library-entry/v1",
  "id": "10665-97885",
  "blocks": [
    {
      "id": "library/10665-97885/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 5,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "Immunization, Vaccines and Biologicals\nThe Immunological Basis\nfor Immunization Series\nModule 16: \nMumps\nImmunization, Vaccines and Biologicals\nThe Immunological Basis\nfor Immunization Series\nModule 16: \nMumps\nWHO Library Cataloguing-in-Publication Data\nThe immunological basis for immunization series: module 16: mumps / by Huong Q Mclean, Carole J Hickman and Jane F Seward.\n(Immunological basis for immunization series ; module 16)\n1.Mumps - immunology. 2.Mumps virus - immunology. 3.Mumps vaccine - therapeutic use. 4.Immunization. I.Mclean, Huong Q. II.Hickman, C. \nJ. III.Seward, Jane F. IV.Wor",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The front matter of Module 16 on mumps in WHO's Immunological Basis for Immunization series, by Huong McLean, Carole Hickman and Jane Seward. It contains the title pages, cataloguing data and keywords, copyright notice and standard WHO disclaimers. It states that responsibility for the views in the module rests with its authors.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Contents",
      "pageStart": 5,
      "pageEnd": 7,
      "target": "../sections/sec-000-contents.md",
      "narrative": null,
      "content": "Abbreviations and acronyms..............................................................................................v\nPreface............................................................................................................................... vii\n1. \t\nMumps disease and virus.......................................................................................1\n1.1\t\nMumps disease  ..............................................................................................1\n1.2\t\nMumps virus .........................................................................................",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The table of contents of the mumps module, listing sections on the disease and virus, vaccines, immune response to infection and vaccination, laboratory diagnosis, vaccine performance and references.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Abbreviations and acronyms",
      "pageStart": 7,
      "pageEnd": 9,
      "target": "../sections/sec-001-abbreviations-and-acronyms.md",
      "narrative": null,
      "content": "acronyms\nCI\t\n\tconfidence interval\nCMI\t\n\tcell-mediated immunity\nCTL\t\n\tcytotoxic T-cell\nDNA\t\n\tdeoxyribonucleic acid\nEIA\t\n\tenzyme immunoassay\nELISA\t\n\tenzyme-linked immunosorbent assay\nF\t\n\tfusion protein\nHLA\t\n\thistocompatibility leukocyte antigen\nHN\t\n\thaemagglutinin-neuraminidase protein\nIg\t\n\timmunoglobulin\nL\t\n\tlarge protein\nM\t\n\tmatrix protein\nMMR\t\n\tmeasles, mumps, and rubella \nNP\t\n\tnucleoprotein\nP\t\n\tphosphoprotein\nPAHO\t\n\tPan American Health Organization\nRNA\t\n\tribonucleic acid\nRT-PCR\t\n\treverse transcriptase-polymerase chain reaction\nSH\t\n\tshort hydrophobic protein\nUSA\t\n\tUnited States of America\nWHO",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the abbreviations and acronyms used in the mumps module, mostly immunology, laboratory and viral protein terms.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Preface",
      "pageStart": 9,
      "pageEnd": 11,
      "target": "../sections/sec-002-preface.md",
      "narrative": null,
      "content": "This module is part of the series The Immunological Basis for Immunization, \nwhich was initially developed in 1993 as a set of eight modules focusing on the vaccines \nincluded in the Expanded Programme on Immunization (EPI)1. In addition to a general \nimmunology module, each of the seven other modules covered one of the vaccines \nrecommended as part of the EPI programme, i.e. diphtheria, measles, pertussis, polio, \ntetanus, tuberculosis and yellow fever. These modules have become some of the most \nwidely used documents in the field of immunization.\nWith the development of the Global Immunizati",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The preface explains that the Immunological Basis for Immunization series began in 1993 with eight modules on the vaccines of the Expanded Programme on Immunization and has been widely used. It notes that the series is being updated and extended with new modules, including this one on mumps.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Mumps disease and virus",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../sections/sec-003-1-mumps-disease-and-virus.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Mumps disease",
      "pageStart": 11,
      "pageEnd": 12,
      "target": "../sections/sec-004-11-mumps-disease.md",
      "narrative": null,
      "content": "Mumps disease  \nMumps is an acute viral illness characterized by unilateral or bilateral tenderness \nor swelling of the parotid or other salivary glands. Mumps is transmitted through \nperson-to-person contact or by direct contact with respiratory droplets or saliva from \nan infected person. By comparison to measles and varicella, which can be transmitted \nby aerosol spread, mumps is less infectious (Hope-Simpson, 1952). The mumps virus \nreplicates in the nasopharynx and regional lymph nodes, with a secondary viremia \noccurring late in the incubation period. During those three to five days of v",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes mumps as an acute viral illness marked by swelling of the parotid or other salivary glands, spread by contact with respiratory droplets or saliva and less infectious than measles or varicella. It explains how the virus replicates and spreads in the body and the timing of infectiousness. It lists complications such as orchitis, meningitis, encephalitis and deafness, with their frequencies.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Mumps virus",
      "pageStart": 12,
      "pageEnd": 12,
      "target": "../sections/sec-005-12-mumps-virus.md",
      "narrative": null,
      "content": "Mumps virus \nMumps virus is a single-stranded, negative sense, enveloped ribonucleic acid \n(RNA) virus in the Paramyxoviridae family, Paramyxovirinae sub-family, genus \nRubulavirus. Mumps virions are pleomorphic but generally spherical structures, and \nrange in size from 85 nm to 300 nm in diameter (Cantell, 1961). The viral genome is \n15 384 nucleotides in length and encodes nine proteins from seven genes. The \nmumps genome is encapsidated by nucleoprotein (NP) and the phosphoprotein \n(P) and large (L) protein are associated with the encapsidated RNA to comprise the \nribonucleoprotein complex",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the mumps virus as an enveloped, negative-sense RNA virus in the Paramyxoviridae family, with its size, genome and the proteins encoded by its genes. It notes the roles of the structural and nonstructural proteins and the genotyping scheme.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Mumps vaccines",
      "pageStart": 12,
      "pageEnd": 17,
      "target": "../sections/sec-006-13-mumps-vaccines.md",
      "narrative": null,
      "content": "Mumps vaccines  \nThe first mumps vaccine was developed in 1946 (Habel, 1946). It was based on formalin-\ninactivated virus, but was discontinued because immunity was short-lived (Habel, 1951). \nSince then numerous mumps vaccine strains have been developed and used in vaccines \nthroughout the world. These vaccines have varied efficacy and safety profiles.\n3\n1.3.1\t Jeryl Lynn \nThe first live attenuated mumps vaccine using the Jeryl Lynn strain was developed in the \nUnited States of America (USA) using an isolate from a child with mumps, and passaged \nin embryonated hens’ eggs and chick embryo cel",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reviews mumps vaccines from the first inactivated vaccine of 1946, discontinued because immunity was short-lived, to the many live attenuated strains used since. It describes strains such as Jeryl Lynn, Urabe, Leningrad-3 and others, including how they were developed. A table compares reported rates of aseptic meningitis after vaccination with different strains in various countries.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 1: Incidence of aseptic meningitis following mumps vaccination",
      "pageStart": 15,
      "pageEnd": 16,
      "target": "../tables/table-1.csv",
      "narrative": "draft",
      "content": "Studies of aseptic meningitis after mumps vaccination, grouped by vaccine strain (Jeryl Lynn/RIT 4385, Urabe Am 9, Leningrad 3, L-Zagreb, Torii, Hoshino). For each study the table gives the country, number of doses, population vaccinated, how cases were ascertained and the incidence per 100 000 doses.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Immunological response to natural infection",
      "pageStart": 17,
      "pageEnd": 17,
      "target": "../sections/sec-007-2-immunological-response-to-natural-infection.md",
      "narrative": null,
      "content": "The immune response to mumps virus infection is likely to be the result of a complex \ninterplay between both the humoral and cellular arms of the immune response, \nand no definitive correlates of protection have yet been identified. Studies on the immune \nresponse to mumps infection are quite limited in comparison to those described for \nmeasles and rubella infections.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that immunity after natural mumps infection probably involves both antibodies and cellular immunity, that no definitive correlates of protection exist, and that research is limited compared with measles and rubella.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Antibody response to mumps infection in unvaccinated individuals",
      "pageStart": 17,
      "pageEnd": 17,
      "target": "../sections/sec-008-21-antibody-response-to-mumps-infection-in-unvac.md",
      "narrative": null,
      "content": "Antibody response to mumps infection in unvaccinated individuals\nIn naive individuals immunoglobulin M (IgM) antibodies are measurable within a \nfew days of symptom onset. IgM peaks about one week after the onset of parotitis or \nsymptoms, and is detectable for weeks to months after parotitis onset (Ukkonen et al., \n1981; Benito et al., 1987). Low avidity IgG may also be present at the time of symptom \nonset, although generally at a low level (Narita et al., 1998). IgG antibody increases \nrapidly and reaches maximum levels about three weeks after onset of symptoms. \nIgG antibodies remain at th",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the antibody response to mumps in unvaccinated people, with IgM appearing within days of symptoms and peaking around one week. IgG rises to a peak in about three weeks and persists, while salivary IgA can be detected for several weeks.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Cell-mediated immunity following natural mumps disease",
      "pageStart": 17,
      "pageEnd": 18,
      "target": "../sections/sec-009-22-cell-mediated-immunity-following-natural-mump.md",
      "narrative": null,
      "content": "Cell-mediated immunity following natural mumps disease\nLymphocytes are known to play an important role in host response to viral infections, \nand are believed to have a significant function in the immune response to mumps and \nrecovery from mumps infection. While the presence of a plaque reduction neutralization \ntitre to mumps appears to be associated with the development of mumps immunity, \nless is known about the development, significance, and function of mumps-specific \ncell-mediated immunity (CMI). Specific lymphocyte mediated cytotoxicity has been \nshown to correlate well with the presen",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes cell-mediated immunity after natural mumps, noting that lymphocytes are thought to aid recovery but that little is known about mumps-specific cellular immunity. It cites studies linking cytotoxic and proliferative lymphocyte responses with infection.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Maternal antibody",
      "pageStart": 18,
      "pageEnd": 18,
      "target": "../sections/sec-010-23-maternal-antibody.md",
      "narrative": null,
      "content": "Maternal antibody\nMaternal antibody (IgG) to mumps following natural infection is transferred across \nthe placenta and is believed to provide protection to infants against clinical mumps. \nClinical mumps occurs less frequently in infants aged less than one year (12% to 17%) \ncompared to children aged one to four years (68%) (Philip et al., 1959; Meyer, 1962; \nReed et al., 1967). Also, during an outbreak, two out of three infants under 12 months \nof age born to mothers with no history of clinical mumps developed mumps after \nexposure, while no infants under 12 months of age born to 10 mothers w",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that maternal antibodies to mumps cross the placenta and likely protect infants, citing lower mumps rates in infants under one year. It reports studies on how long maternal antibodies remain detectable during the first year.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Duration of immunity to natural mumps infection",
      "pageStart": 18,
      "pageEnd": 19,
      "target": "../sections/sec-011-24-duration-of-immunity-to-natural-mumps-infecti.md",
      "narrative": null,
      "content": "Duration of immunity to natural mumps infection\nNatural mumps virus infection is generally believed to provide long-lasting immunity. \nTwenty or more years after their mumps illness, most (82%) individuals still had \ndetectable haemagglutination-inhibiting antibodies (Levitt et al., 1970). However, \ncases of clinically apparent mumps reinfection that have been confirmed with \nepidemiological links or laboratory tests have been reported (Meyer, 1962; Gut et al., \n1995; Crowley & Afzal, 2002; Yoshida et al., 2008), and may be more common than \npreviously thought.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that natural mumps infection is generally thought to give long-lasting immunity, though confirmed reinfections have been reported and may be more common than believed.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Immunological response to vaccination",
      "pageStart": 19,
      "pageEnd": 19,
      "target": "../sections/sec-012-3-immunological-response-to-vaccination.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Antibody response following vaccination",
      "pageStart": 19,
      "pageEnd": 21,
      "target": "../sections/sec-013-31-antibody-response-following-vaccination.md",
      "narrative": null,
      "content": "Antibody response following vaccination\nIn general, over 90% of infants and children develop detectable antibodies against \nmumps following vaccination with mumps vaccines (Table 2). Seroconversion rates \nare comparable for vaccine combinations with Jeryl Lynn, RIT 4385 and Urabe Am \n9 strains (Isomura et al., 1973; Vesikari et al., 1983b; Usonis et al., 1998; Usonis et \nal., 1999; Usonis et al., 2001; Lee et al., 2002) except for one study that suggested \nhigher serconversion for children receiving vaccines containing Urabe Am 9 than \nthose receiving Jeryl Lynn-containing vaccines (Vesikari e",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports that over 90% of children develop mumps antibodies after vaccination, with similar seroconversion across major vaccine strains, and discusses responses to one and two doses. A table summarizes seroconversion studies. It notes that revaccination raised antibody titres in more than half of recipients and reduced the share with low titres.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 2: Seroconversion following mumps vaccination",
      "pageStart": 20,
      "pageEnd": 20,
      "target": "../tables/table-2.csv",
      "narrative": "draft",
      "content": "Seroconversion after mumps vaccination by vaccine strain and formulation (monovalent, bivalent, trivalent, tetravalent). For each strain the table gives the number of studies, the median and range of seroconversion (%) and the references.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Cell-mediated immunity following mumps vaccination",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../sections/sec-014-33-cell-mediated-immunity-following-mumps-vaccin.md",
      "narrative": null,
      "content": "Cell-mediated immunity following mumps vaccination\nFollowing vaccination with live attenuated mumps vaccine, most, but not all children \nwith anti-mumps antibody in their sera, demonstrated a lymphocyte proliferative \nresponse to mumps antigen (Ilonen, 1979; Ilonen et al., 1984). Unlike the humoral \nimmune response to mumps, cellular responses were equivalent in all age groups and \nwere independent of the presence of maternal antibody (Gans et al., 2001). In addition, \nassociations of specific histocompatibility leukocyte antigen (HLA) haplotypes \nwith higher or lower frequencies of mumps anti",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports that most vaccinated children with mumps antibodies also show lymphocyte responses, that cellular responses are similar across ages regardless of maternal antibody, and that HLA associations suggest genetic influence on the immune response.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Duration of immunity to mumps vaccination",
      "pageStart": 21,
      "pageEnd": 22,
      "target": "../sections/sec-015-34-duration-of-immunity-to-mumps-vaccination.md",
      "narrative": null,
      "content": "Duration of immunity to mumps vaccination \nData regarding long-term immunity against mumps after vaccination are limited. \nStudies indicate that one dose of MMR vaccine can provide persistent antibodies \nto mumps. Between 70% and 99% of individuals had detectable anti-mumps \nantibodies using enzyme-linked immunosorbent assay (ELISA) or neutralization tests \napproximately ten years after initial vaccination (Broliden et al., 1998; Gothefors et al., \n2001; LeBaron et al., 2009) (Table 3). Differences in laboratory method may account for \nthe wide variation in detection rates. In addition, among",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that data on long-term immunity after mumps vaccination are limited, though antibodies persist in most people about ten years after one MMR dose, with variation by laboratory method. It discusses waning antibody levels after two doses. It ends by listing open questions on cellular immunity and boosting from exposure to wild virus.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/table-003",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3: Long-term persistence of mumps antibodies following vaccination with mumps Jeryl Lynn vaccine",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../tables/table-3.csv",
      "narrative": "draft",
      "content": "Studies of long-term persistence of mumps antibodies after one or two doses of Jeryl Lynn mumps vaccine. For each study the table gives the country, years since vaccination, the number seropositive out of the number tested (%) and the serological method used.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Correlates of immunity",
      "pageStart": 22,
      "pageEnd": 24,
      "target": "../sections/sec-016-35-correlates-of-immunity.md",
      "narrative": null,
      "content": "Correlates of immunity\nHumoral immunity is important in protection against mumps, and antibody \nmeasurements are often used as a surrogate measure of immunity to viral infections. \nHowever, there is poor correlation between assays that measure neutralization and less \nlabour-intensive methods that measure the presence of mumps antibody (Pipkin et al., \n1999). While no serological test available for mumps consistently and reliably predicts \nimmunity, neutralizing antibodies appear to be a reasonable marker for immunity. \nAntibodies directed against haemagglutinin-neuraminidase protein (HN) have",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses correlates of immunity to mumps, explaining that neutralizing antibodies seem a reasonable marker though no serological test reliably predicts protection. It calls for more research, including on cell-mediated immunity markers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Laboratory diagnosis of mumps",
      "pageStart": 24,
      "pageEnd": 24,
      "target": "../sections/sec-017-4-laboratory-diagnosis-of-mumps.md",
      "narrative": null,
      "content": "14\nA clinical diagnosis of mumps is frequently made when parotitis is evident at the time \nof patient examination. However, since parotitis may be caused by other viral or non-\nviral diseases or conditions, laboratory confirmation using virological or serological \ntechniques may be needed, especially as mumps disease becomes rare due to increased \nvaccination.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes that mumps is often diagnosed clinically from parotitis but that laboratory confirmation may be needed because other causes exist and mumps is becoming rare.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Virological methods",
      "pageStart": 24,
      "pageEnd": 24,
      "target": "../sections/sec-018-41-virological-methods.md",
      "narrative": null,
      "content": "Virological methods\nMumps virus is stable for several days at 4°C. Stability increases with decreasing \ntemperature and the virus can be stored indefinitely at -70°C. Specimen quality \nappears to greatly impact the ability to culture mumps virus and detect mumps \nRNA using reverse transcriptase-polymerase chain reaction (RT-PCR) (Utz et al., \n1958). Mumps virus and RNA can be detected from blood, saliva, cerebrospinal \nfluid and urine. However, the sensitivity of mumps RNA detection in urine is poor \n(Krause et al., 2006). Since mumps virus replication is transient, there is a limited \ntimefra",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes virological methods for diagnosing mumps, including virus stability in storage, specimen types and timing of collection. It notes that RNA detection by RT-PCR is generally more sensitive than culture.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Serological methods",
      "pageStart": 24,
      "pageEnd": 25,
      "target": "../sections/sec-019-42-serological-methods.md",
      "narrative": null,
      "content": "Serological methods\nDetection of mumps-specific IgM antibody in serum or saliva is a good diagnostic \nmeasure in unvaccinated patients. Timing of specimen collection is important to \nconsider in interpreting laboratory results. Negative IgM ELISA results may occur \nwhen serum is collected prior to day four of clinical presentation (Cunningham et al., \n2006; Krause et al., 2007). By contrast, patients who mount a secondary immune \nresponse, as occurs in the majority of vaccinated mumps cases, may not have an \nIgM response, or it may be transient and not detected depending on timing of specimen",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes serological diagnosis of mumps, explaining that IgM detection works well in unvaccinated patients if specimens are well timed but may fail in vaccinated people with a secondary immune response. A table sets out expected laboratory results by vaccination status and timing of collection.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Diagnostic challenges",
      "pageStart": 25,
      "pageEnd": 26,
      "target": "../sections/sec-020-43-diagnostic-challenges.md",
      "narrative": null,
      "content": "Diagnostic challenges\nLaboratory diagnosis of mumps in highly-vaccinated populations is challenging, \nand new laboratory tools and diagnostic approaches are needed to accurately identify \ncases and better understand the epidemiology of mumps in highly-vaccinated \npopulations. During the 2006 mumps outbreak in the USA, the majority of patients \nwho had received two doses of MMR and presented with symptoms that were clinically \ncompatible with mumps could not be laboratory confirmed using the serological, \nvirological, or molecular methods that have been so successful in confirming mumps \nin unv",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that laboratory diagnosis of mumps is difficult in highly vaccinated populations, as shown in the 2006 US outbreak, and that RT-PCR and culture are the best current tests for vaccinated people.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/table-004",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 4: Immune response to mumps wild-type infection based on exposure history",
      "pageStart": 25,
      "pageEnd": 25,
      "target": "../tables/table-4.csv",
      "narrative": "draft",
      "content": "Expected antibody findings in wild-type mumps infection according to prior exposure (unvaccinated, one or two vaccine doses, previous wild-type infection). Columns give IgM, IgG and avidity results, comments on IgM detection, and references.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Vaccine performance",
      "pageStart": 26,
      "pageEnd": 26,
      "target": "../sections/sec-021-5-vaccine-performance.md",
      "narrative": null,
      "content": "16",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A section heading for vaccine performance, containing only a page number.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Vaccine efficacy",
      "pageStart": 26,
      "pageEnd": 26,
      "target": "../sections/sec-022-51-vaccine-efficacy.md",
      "narrative": null,
      "content": "Vaccine efficacy\nPrelicensure studies conducted in over 7000 children enrolled in nursery or elementary \nschools found a single dose of mumps vaccines containing the Jeryl Lynn strain to \nbe approximately 95% effective in preventing mumps disease (Hilleman et al., 1967; \nWeibel et al., 1967; Sugg et al., 1968). However, duration of follow-up was short \n(up to 20 months). In a smaller study, with 193 children exposed to persons with \nclinical mumps, the efficacy of the mumps vaccine containing the Leningrad-3 strain \nwas 94% (95% CI: 76% to 98%) (Smorodintsev et al., 1965). Additional studies u",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports prelicensure studies showing a single dose of Jeryl Lynn mumps vaccine was about 95% effective over short follow-up, and high efficacy for Leningrad-3 strain vaccines.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Vaccine effectiveness",
      "pageStart": 26,
      "pageEnd": 30,
      "target": "../sections/sec-023-52-vaccine-effectiveness.md",
      "narrative": null,
      "content": "Vaccine effectiveness\n5.2.1\t Vaccine effectiveness of one dose\nIn postlicensure studies, vaccine effectiveness estimates for prevention of mumps \ndisease have been lower (Table 5). In 18 studies from outbreaks (primarily school\nchildren) in North America and Europe, the median estimate for vaccine effectiveness \nof one dose of the Jeryl Lynn mumps vaccine was 79% (range: 62% to 91%) \n(Lewis et al., 1979; Kim-Farley et al., 1985; Sullivan et al., 1985; Chaiken et al., 1987; \nWharton et al., 1988; Hersh et al., 1991; Cheek et al., 1995; Toscani et al., 1996; \nChamot et al., 1998; Schlegel et al.",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reviews postlicensure vaccine effectiveness from outbreak studies, with a median of 79% for one dose of Jeryl Lynn vaccine and lower figures for the Urabe strain. It reports that the Rubini strain showed little or no effectiveness and is no longer available. Two-dose Jeryl Lynn effectiveness had a median of 88%, usually but not significantly higher than one dose. It calls for research linking protection to neutralizing antibody levels and on the role of heterologous mumps strains.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-97885/blocks/table-005",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5: Mumps vaccine effectiveness",
      "pageStart": 27,
      "pageEnd": 28,
      "target": "../tables/table-5.csv",
      "narrative": "draft",
      "content": "Post-licensure estimates of mumps vaccine effectiveness, grouped by vaccine strain and, for Jeryl Lynn, by one or two doses. For each study the table gives the country, study population, number in study and vaccine effectiveness (%) with 95% confidence intervals where available.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-97885/blocks/prose-sec-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 30,
      "pageEnd": 44,
      "target": "../sections/sec-024-references.md",
      "narrative": null,
      "content": "20\nAfzal MA et al. (1993). The Jeryl Lynn vaccine strain of mumps virus is a mixture of \ntwo distinct isolates. The Journal of General Virology, 74 (Pt. 5):917–920.\nAl-Mazrou Y et al. (2002). Safety evaluation of MMR vaccine during a primary school \ncampaign in Saudi Arabia. Journal of Tropical Pediatrics, 48(6):354–358.\nArday DR et al. (1989). Mumps in the US Army 1980–86: should recruits be immunized? \nAmerican Journal of Public Health, 79(4):471–474.\nArruda WO, Kondageski C (2001). Aseptic meningitis in a large MMR vaccine campaign \n(590,609 people) in Curitiba, Parana, Brazil, 1998. Revist",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for the mumps module, citing mainly published studies on mumps epidemiology, vaccine safety and effectiveness, immunology and laboratory diagnosis. It ends with WHO's Department of Immunization, Vaccines and Biologicals contact details and the ISBN.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    }
  ]
}
